PIK3CA-related overgrowth spectrum (PROS) is a rare genetic disorder that causes uncontrollable growth of parts of the body. Its symptoms vary greatly and affect children physically and ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease. The mutation occurs in around 40% of ...

Because of the frequent mutational activation of Ras in cancer, there is widespread interest in developing Ras inhibitors. However, because Ras has many downstream effectors that regulate complex ...

The Novartis drug PIQRAYTM (alpelisib) is the first -selective PI3Kinase inhibitor to be approved by the FDA for treatment of cases of advanced Hormone Receptor +ve / HER2 -ve breast cancer that also ...

The review highlights next-generation therapies that specifically target PIK3CA mutations with improved selectivity and ...

The new drug is suitable for patients’ tumours with mutations or alterations in the PIK3CA, AKT1 or PTEN genes, which are found in approximately half of patients with this form of breast cancer.

The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...